知镜 Cognispect · 医学文献与研究工作台

Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide.

Carruthers JE, Ooi XY, Goodall D, Reed J, Bedi R, McGrath A, Willicombe M, Avari P, Frankel AH.
Diabetic medicine : a journal of the British Diabetic Association · 2026-10-19 · PMID 42897718

文献摘要

Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials. There have been limited reports of the implications of prescribing tirzepatide in a real-world cohort of patients with advanced CKD. Methods This observational study includes a multi-ethnic cohort of 62 adults with CKD stages 1-5 who initiated tirzepatide indicated for T2DM with concurrent obesity in a general nephrology clinic between June 2024 and October 2025. Patients were followed for a median of 21.4 weeks. Clinical outcomes including weight, glycated haemoglobin (HbA1c), estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (uACR), blood pressure, lipid profile and insulin requirements were collected. Results Tirzepatide significantly reduced median weight (103-100 kg; p Conclusions In this real-world, multi-ethnic cohort, including patients with advanced CKD, tirzepatide was associated with clinically meaningful improvements in weight, glycaemic control, albuminuria, lipid profile and insulin requirements without adversely affecting kidney function. The introduction of tirzepatide to patients with CKD should be guided by a multidisciplinary team.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。